China (Mainland)
Benfotiamine CAS NO.13708-63-9
- FOB Price: USD: 100.00-100.00 /Kilogram Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/P,T/T,
- Product Details
Keywords
- Benfotiamine
- 13708-63-9
- Benfotiamine Powder
Quick Details
- ProName: Benfotiamine
- CasNo: 13708-63-9
- Molecular Formula: C19H23N4O6PS
- Appearance: Raw Material Powder
- Application: APIS
- DeliveryTime: by air 7-15days, by sea 35-55days
- PackAge: 1kg, 5kg, 10kg per bag, 25kg/drum or c...
- Port: Shanghai or Beijing
- ProductionCapacity: 50 Metric Ton/Day
- Purity: 98%
- Storage: Sealed, Cool and Dry Place
- Transportation: 100kg below by express, 100-500kg by a...
- LimitNum: 1 Kilogram
- Grade: Food Grade,Pharma Grade
Superiority
1. Any inquiries will be replied within 12 hours.
2. Dedication to quality, supply & service.
3. Strictly on selecting raw materials.
4. OEM/ODM Available.
5. Reasonable & competitive price, fast lead time.
6. Sample is available for your evaluation & Formulation development.
7. Faster delivery:Sample order in stock and 3-7 days for bulk production.
8. We have strong cooperation with DHL, TNT, UPS, FEDEX, EMS. Or you also can choose your own shipping forwarder.
9. After-Sale Service:
(1) International Authorized Third-Party Test For The Products You Demand.
(2) 60 Days Warranty of quality of goods.
Details
ertificate of Analysis
|
Test |
Specifications |
Result |
|
Assay |
≥98.0% |
Complies |
|
Appearance |
A white to off-white crystalline powder |
Complies |
|
Identification |
IR |
|
|
Water |
≤ 1.5% |
0.4% |
|
Chloride |
≤0.053% |
0.031% |
|
Sulphate |
≤0.011% |
0.005% |
|
Thiamine |
≤0.1% |
0.06% |
|
Benzoic acid |
Negative |
Complies |
|
Melting point |
≤ 200℃ |
Complies |
|
Heavy metal |
≤ 20ppm |
<10ppm |
|
Conclusion |
Conform with In house Standard |
|
Function&Application
Benfotiamine is useful for the treatment of diabetic retinopathy, neuropathy, and nephropathy however "Most of the effects attributed to benfotiamine are extrapolated from in vitro and animal studies. Unfortunately apparent evidences from human studies are scarce and especially endpoint studies are missing. Therefore additional clinical studies are mandatory to explore the therapeutic potential of benfotiamine in both diabetic and non-diabetic pathological conditions".
It is thought that treatment with benfotiamine leads to increased intracellularthiamine diphosphate levels, a cofactor of transketolase. This enzyme directs advanced glycation and lipoxidation end products (AGE's, ALE's) substrates to the pentose phosphate pathway, thus reducing tissue AGEs.
1. Benfotiamine is used for the prevention and treatment of vitamin B1 deficiency;
2. For vitamin B1 demand increase, with inadequate intake from foods supplies (fatigue, hyperthyroidism, pregnancy, lactation, during strenuous manual labor, etc.);
3. Benfotiamine is used in the treatment of non alcoholic wernicke encephalopathy;
4. To treat beriberi;
5. Used in the following diseases, speculation and vitamin B1 deficiency and metabolic disorders associated with treatment, such as: neuralgia; Muscle pain, joint pain; Peripheral neuritis, peripheral nerve palsy; Myocardial metabolic disorders; Constipation and other gastrointestinal motor function obstacle.
